CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing quality pharmaceutical products to the Chinese and U.S. markets announced that it has acquired a portfolio of 25 U.S. FDA-appro……
Janssen Biotech, Inc. announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S on Nov. 22, 2027. Food and Drug Administration (FDA) for DARZALEX? (daratumumab). This application seek……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
